Relmapirazin

瑞玛比嗪

Report date: 2025/10/31 11:20:07
NME

Base Information

Drug NameRelmapirazin
Drug Alias Name瑞美吡嗪LumitraceMediBeacon® TGFRAPC-2MB-102 +[7] 
ClassificationSmall molecules > Heterocyclic drugsDiagnostic agent (In vivo)Drug and medical devices combination products
Mechanisms of ActionDiagnostic imaging enhancers
TargetsNot applicable
Therapy Area/IndicationsDiagnostic agentsRenal Insufficiency, ChronicAcute Kidney Injury +[10] 
Global Approved IndicationsKidney Diseases
Approved Indications in ChinaKidney Diseases
Original Approved Country/TerritoryUnited States
Original Approved Date2025/01/17
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMediBeacon Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesMediBeacon IncAlbany Molecular Research（Glasgow）LtdHangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDiagnostic agentsRenal Insufficiency, ChronicAcute Kidney Injury +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank